Phibro Animal Health Corporation
NASDAQ:PAHCDrug Manufacturers - Specialty & Generic
+$0.38 today
- Market cap
- $1.44B
- Beta
- 0.46
- P/E (TTM)
- 13.3
- EPS (TTM)
- $2.35
- Dividend yield
- 1.54%
Volume 0.11M
Average 0.37M
PAHC Net Income
Bottom-line profit after all expenses, interest, and taxes.
Phibro Animal Health CorporationNASDAQ: PAHC
Net Income · Q3 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $24.02M rose 15.1% year over year, behind the +199.6% change in trailing-twelve-month net income. Sequentially, it fell 12.5% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.
Context
- Net income amounted to 3.7% of revenue in FY2025, up 3.5 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of $125.83M (+160.7%) for the fiscal year ending Jun 2026, a slowdown from the +1897.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $24.02M-12.5% QoQ
- Last fiscal yearJun 2025
- $48.26M+1897.7% YoY
- LTMMar 2026
- $95.23M+199.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 48.26M USD
- Year-over-year change
- +1897.7%
- 4-year CAGR
- -2.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 48.26M | +1897.7% |
| FY2024 | 2024-06-30 | 2.42M | -92.6% |
| FY2023 | 2023-06-30 | 32.61M | -33.7% |
| FY2022 | 2022-06-30 | 49.18M | -9.6% |
| FY2021 | 2021-06-30 | 54.39M | — |
Net Income vs competitors
How PAHC compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +199.6% is the highest of 6, against a peer median of -80.7%.
- Net income amounts to 6.3% of revenue for PAHC, versus a peer median of 6.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.17B USD | -80.7% | +7.9% | 4.8% | |
| LTM Jun 2026 | $2.62B USD | +0.2% | +8.1% | 27.5% | |
| LTM Mar 2026 | $95.23M USD | +199.6% | -0.6% | 6.3% | |
| LTM Aug 2026 | -$56.12M USD | +94.6% | — | 6.3% | |
| FY2025 | -CN¥69.78M CNY | -717.0% | — | 60.0% | |
| LTM Sep 2026 | -$147M USD | -508.3% | — | 2.9% | |
| Peer median (excluding PAHC) | — | -80.7% | +8.0% | 6.3% | |
Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 833.35M | 942.26M | 977.89M | 1.02B | 1.3B |
| Cost of Revenue | 561.97M | 656.86M | 679.65M | 704.59M | 896.27M |
| Gross Profit | 271.38M | 285.4M | 298.24M | 313.09M | 399.94M |
| Gross Margin | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Operating Expenses | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Depreciation & Amortization | 31.88M | 32.71M | 34.01M | 36.18M | 45.61M |
| EBITDA | 110.21M | 117.13M | 106.03M | 69.06M | 146.85M |
| EBITDA Margin | 13.2% | 12.4% | 10.8% | 6.8% | 11.3% |
| Operating Income | 74.87M | 78.99M | 71.85M | 53.32M | 110.47M |
| Operating Margin | 9.0% | 8.4% | 7.3% | 5.2% | 8.5% |
| Interest Income | 838K | 816K | 3.36M | 4.47M | 2.62M |
| Interest Expense | 10.4M | 12.1M | 17.95M | 21.97M | 33.25M |
| Other Income / Expenses | (8.4M) | (6.66M) | (17.78M) | (42.4M) | (42.47M) |
| Income Before Tax | 66.47M | 72.33M | 54.07M | 10.92M | 67.99M |
| Pre-Tax Margin | 8.0% | 7.7% | 5.5% | 1.1% | 5.2% |
| Income Tax Expense | 12.08M | 23.15M | 21.47M | 8.5M | 19.73M |
| Net Income | 54.39M | 49.18M | 32.61M | 2.42M | 48.26M |
| Net Margin | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
| EPS (Basic) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| EPS (Diluted) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| Weighted Avg Shares | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M |
| Weighted Avg Shares (Diluted) | 40.5M | 40.5M | 40.5M | 40.52M | 40.7M |
Phibro Animal Health Corporation
NASDAQ:PAHC
Intrinsic Alpha fair value
Locked
Current Price
$35.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.